Cutaneous Lymphomas News Today

Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company...

Skin cancer is the most common cancer in the world. HELLO! spoke to Dr. Peter Dziewulski to understand the disease in more detail, including signs, types and treatment options

MARSEILLE, France, October 05, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The partial clinical hold follows one fatal case of hemophagocytic lymphoh...

The retrospective study analyzed data on 149 patients with CTCL who were being managed at one of nine international academic medical centers in seven countries from March through October 2020.

Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients with myco

/PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, will host a...

NICE uphold appeal by Kyowa Kirin, for POTELIGEO in the treatment of those living with certain ultra-rare blood cancers The National Institute for Health and Care Excellence (NICE) has upheld an appeal

Patients treated with POTELIGEO? (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the

Patients treated with POTELIGEO®▼ (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the European Hematology Association meeting1GALASHIELS, Scotland--(BUSINESS WIRE)--Kyowa Kirin International PLC (Kyowa Ki...

Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab) two very rare forms of non-Hodgkin lymphoma will not have access to an innovative systemic treatment following NICEs decision to not recommend mogamulizumab for routine use in the NHS . Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE. The National Instit...